Payment overview · 2025
General Payments
$891.85
48 reported records · 20 companies
Healthcare provider profile · identity verified
Devin A Mcmanus, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FALMOUTH, MA · NPI 1548263486
Verified facts
What the public records show
CMS Open Payments records show Devin A Mcmanus, M.D. received $891.85 in general payments during 2025 across 48 reported records.
Amgen Inc. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $156.31 | 17.5% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.43 | 11.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.20 | 9.9% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $70.27 | 7.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.43 | 6.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.38 | 5.9% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.00 | 5.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $39.22 | 4.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $36.66 | 4.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.97 | 3.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.81 | 3.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.26 | 2.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.36 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.30 | 2.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.46 | 2.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.70 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.61 | 2.0% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $17.29 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.08 | 1.9% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $15.11 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $871.63 | 47 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $131.19 | 13 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $88.20 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $55.15 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.38 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $47.86 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.28 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $39.22 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $36.66 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 491 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 64 |
| Lisinopril | Lisinopril | 223 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 47 |
| Losartan Potassium | Losartan Potassium | 150 | 39 |
| Omeprazole | Omeprazole | 148 | 47 |
| Gabapentin | Gabapentin | 143 | 35 |
| Lorazepam | Lorazepam | 141 | 36 |
| Metformin Hcl | Metformin Hcl | 135 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 36 |
| Trazodone Hcl | Trazodone Hcl | 110 | 24 |
| Simvastatin | Simvastatin | 106 | 29 |
| Furosemide | Furosemide | 101 | 27 |
| Celecoxib | Celecoxib | 99 | 28 |
| Allopurinol | Allopurinol | 96 | 27 |
| Alprazolam | Alprazolam | 91 | 17 |
| Atenolol | Atenolol | 85 | 17 |
| Lovastatin | Lovastatin | 84 | 18 |
| Prednisone | Prednisone | 78 | 40 |
| Glimepiride | Glimepiride | 77 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 68 | 20 |
| Eliquis | Apixaban | 67 | 14 |
| Tramadol Hcl | Tramadol Hcl | 67 | 14 |
| Ozempic | Semaglutide | 65 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 20 |
| Donepezil Hcl | Donepezil Hcl | 59 | 14 |
| Potassium Chloride | Potassium Chloride | 59 | 16 |
| Spironolactone | Spironolactone | 59 | 14 |
| Methylprednisolone | Methylprednisolone | 57 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 18 |
| Finasteride | Finasteride | 54 | 12 |
| Synthroid | Levothyroxine Sodium | 54 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Carvedilol | Carvedilol | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 17 |
| Valsartan | Valsartan | 41 | 16 |
| Meclizine Hcl | Meclizine Hcl | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 18 |
| Ibuprofen | Ibuprofen | 39 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 38 | suppressed |
| Jardiance | Empagliflozin | 37 | 13 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Naproxen | Naproxen | 26 | 11 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Estradiol | Estradiol | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 15 |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Armodafinil | Armodafinil | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 12 |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $891.85 · 48 records | Amgen Inc. | ABRYSVO, AIRSUPRA, BREZTRI, Bimzelx, COMIRNATY, CONTRAVE, Cologuard Collection Kit, EVENITY, INSPIRE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, ONPATTRO, OTEZLA, PAXLOVID, PREVNAR 20, PROLIA, REPATHA, REXULTI, SHINGRIX, VOQUEZNA, Wegovy, YUPELRI, ZENPEP, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error